BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23462923)

  • 41. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
    Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
    Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis.
    Henderson MA; Danks JA; Slavin JL; Byrnes GB; Choong PF; Spillane JB; Hopper JL; Martin TJ
    Cancer Res; 2006 Feb; 66(4):2250-6. PubMed ID: 16489028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship of plasma bone cytokines with hypercalcemia in cancer patients.
    Motellón JL; Jiménez FJ; de Miguel F; Jaras MJ; Díaz A; Hurtado J; Esbrit P
    Clin Chim Acta; 2000 Dec; 302(1-2):59-68. PubMed ID: 11074064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer.
    Zhao FL; Hu GD; Wang XF; Zhang XH; Zhang YK; Yu ZS
    J Int Med Res; 2012; 40(3):859-66. PubMed ID: 22906258
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Markers of bone metastases in breast and lung cancers.
    Bilgin E; Yasasever V; Soydinc HO; Yasasever CT; Ozturk N; Duranyildiz D
    Asian Pac J Cancer Prev; 2012; 13(9):4331-4. PubMed ID: 23167338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunoarray Measurements of Parathyroid Hormone-Related Peptides Combined with Other Biomarkers to Diagnose Aggressive Prostate Cancer.
    Dhanapala L; Joseph S; Jones AL; Moghaddam S; Lee N; Kremer RB; Rusling JF
    Anal Chem; 2022 Sep; 94(37):12788-12797. PubMed ID: 36074029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PTHrP regulates angiogenesis and bone resorption via VEGF expression.
    Isowa S; Shimo T; Ibaragi S; Kurio N; Okui T; Matsubara K; Hassan NM; Kishimoto K; Sasaki A
    Anticancer Res; 2010 Jul; 30(7):2755-67. PubMed ID: 20683010
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells.
    Hoey RP; Sanderson C; Iddon J; Brady G; Bundred NJ; Anderson NG
    Br J Cancer; 2003 Feb; 88(4):567-73. PubMed ID: 12592371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum concentration of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with metastatic breast cancer.
    Maemura M; Iino Y; Yokoe T; Takei H; Horiguchi J; Koibuchi Y; Ikeda F; Ohwada S; Takeyoshi I; Morishita Y
    Oncol Rep; 2000; 7(6):1333-8. PubMed ID: 11032939
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.
    Johnson RW; Nguyen MP; Padalecki SS; Grubbs BG; Merkel AR; Oyajobi BO; Matrisian LM; Mundy GR; Sterling JA
    Cancer Res; 2011 Feb; 71(3):822-31. PubMed ID: 21189326
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites.
    Powell GJ; Southby J; Danks JA; Stillwell RG; Hayman JA; Henderson MA; Bennett RC; Martin TJ
    Cancer Res; 1991 Jun; 51(11):3059-61. PubMed ID: 2032246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition effects of total flavonoids from Sculellaria barbata D. Don on human breast carcinoma bone metastasis via downregulating PTHrP pathway.
    Zheng X; Kang W; Liu H; Guo S
    Int J Mol Med; 2018 Jun; 41(6):3137-3146. PubMed ID: 29512770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiple actions of parathyroid hormone-related protein in breast cancer bone metastasis.
    Martin TJ; Johnson RW
    Br J Pharmacol; 2021 May; 178(9):1923-1935. PubMed ID: 31087800
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy.
    Lumachi F; Basso SM; Camozzi V; Tozzoli R; Spaziante R; Ermani M
    Clin Chim Acta; 2016 Sep; 460():227-30. PubMed ID: 27404457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
    Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
    Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activin A circulating levels in patients with bone metastasis from breast or prostate cancer.
    Leto G; Incorvaia L; Badalamenti G; Tumminello FM; Gebbia N; Flandina C; Crescimanno M; Rini G
    Clin Exp Metastasis; 2006; 23(2):117-22. PubMed ID: 16841234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
    Ferreira AR; Alho I; Shan N; Matias M; Faria M; Casimiro S; Leitzel K; Ali S; Lipton A; Costa L
    Oncologist; 2016 Dec; 21(12):1418-1426. PubMed ID: 27534575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
    Yin JJ; Selander K; Chirgwin JM; Dallas M; Grubbs BG; Wieser R; Massagué J; Mundy GR; Guise TA
    J Clin Invest; 1999 Jan; 103(2):197-206. PubMed ID: 9916131
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical studies using measurement of N-telopeptides of type 1 collagen (NTx) in patients with bone metastasis--comparison with bone scintigraphy and other metabolic bone markers].
    Yamamoto I; Morita R; Konishi J; Shigeno C; Ikekubo K; Hino M; Sone T; Fujimoto R
    Kaku Igaku; 1995 May; 32(5):501-10. PubMed ID: 7596071
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
    Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
    Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.